ultrasound guided prostate biopsy. The authors studied 367 patients undergoing a prostate biopsy and divided into 2 groups according to prophilaxy: oral ciprofloxacin (750 mg every 12 hours) for 3 or more days in Group-1 and single day in Group-2 and concluded that in a selected patient population single dose prophylaxis with ciprofloxacin can be safely administered compared to other regimens of 3 or more days. Increasing the duration of antibiotic prophylaxis does not decrease infectious complications.
The 4 papers are very interesting but what is the future of the prostate biopsy? The answer is Multiparametric Magnetic Resonance Imaging MRI/TRUS fusion prostate biopsy.
Multiparametric Magnetic Resonance Imaging (MRI) is emerging as a powerful test to diagnose and stage prostate cancer (PCa) (1) . Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) correctly identified 95 % of PCa foci ≥ 0.5 mL, but the PI-RADSv2 was limited for the assessment of GS ≥ 4+3 tumours ≤ 0.5 mL (2) . Quantitative MRI parameters can predict malignant histology on MRI/TRUS fusion prostate biopsy, which is a valuable technique to ensure adequate sampling of MRI-visible suspicious lesions under TRUS guidance and may impact patient management (3).
